[Development of tuberculosis after treatment with the TNF-alpha inhibitor infliximab].
Dahl
Morten
M
Infektionsmedicinsk Afdeling, H:S Hvidovre Hospital. mortendahl@mail.tdcadsl.dk
Ravn
Pernille
P
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D014397:Tuberculosis, Pulmonary / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D005765:Gastrointestinal Agents; D000069285:Infliximab